IL17A and neoplasm: To date, however, we are not aware of completed clinical trials which have focused on the administration of MAbs targeting either IL17A or its receptor as a potential strategy to enhance the efficacy of anti-tumor chemotherapy and/or ICI-based immunotherapy.